復星醫藥(600196.SH):控股子公司就ET-26用於成人全身麻醉誘導於中國境內啟動III期臨牀試驗
格隆匯10月16日丨復星醫藥(600196.SH)公佈,控股子公司錦州奧鴻藥業有限責任公司就ET-26(即注射用甲氧依託咪酯鹽酸鹽)用於成人全身麻醉誘導於中國境內(不包括港澳台地區)啟動III期臨牀試驗。
該新藥於臨牀前由本集團受讓,並後續與四川大學華西醫院共同研發。截至本公吿日,該新藥用於成人全身麻醉誘導已於中國境內完成II期臨牀試驗。該新藥是咪唑類靜脈全身麻醉藥,擬用於全身麻醉的誘導,以及短小外科手術及診斷性檢查時的鎮靜或用於重症監護患者的鎮靜;同類藥物為丙泊酚和依託咪酯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.